Fundz

Cytokinetics

South San Francisco, California, United States · Biotechnology, Health Care, Therapeutics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug c

Key facts

Headquarters
South San Francisco, California, United States
Employees
694
Industries
Biotechnology, Health Care, Therapeutics
Status
Public (CYTK)
Website
cytokinetics.com
LinkedIn
Company page

Recent activity at Cytokinetics

  • : SEC 8-K (8.01): On August 28, 2026, Cytokinetics, Incorporated announced through a press release the presentation of the full results of the ACACIA-HCM trial at the European Society of Cardiology (ESC) Congress 2026, with the results also published in the New England Journal of Medicine. This event is significant as it highlights the company's progress in clinical research and may impact investor sentiment regarding Cytokinetics' ongoing projects and future developments in heart failure treatments. The presentation at a prominent congress underlines the importance of the trial findings in the broader medical community.
  • : SEC 8-K (8.01): Cytokinetics, Incorporated filed a complaint in the U.S. District Court for the District of Delaware on August 13, 2026, against Bristol-Myers Squibb Company and MyoKardia, Inc. The complaint seeks a declaratory judgment asserting that Cytokinetics does not infringe U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The company requests a judgment to prevent defendants from threatening or initiating infringement litigation and seeks attorney's fees and other relief. This legal action highlights potential strategic implications for the Company and is part of its efforts to vigorously assert its rights in the patent arena.
  • : SEC 8-K (8.01): On May 6, 2026, Cytokinetics, Incorporated entered into an Underwriting Agreement with Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Jefferies LLC for a public offering of 9,859,155 shares of common stock at $71.00 per share. They granted the underwriters an option, exercised in full on May 7, 2026, to purchase an additional 1,478,873 shares. The total net proceeds from this offering are approximately $760.2 million after deducting fees. This transaction is significant for raising capital for future operations or investments, and the Underwriting Agreement includes customary representations, warranties, and conditions to closing, ensuring compliance with regulatory obligations.
  • : SEC 8-K (8.01): On May 5, 2026, Cytokinetics, Incorporated released a current corporate presentation, which is intended to inform stakeholders about the company’s recent developments and strategic initiatives. This presentation is attached as Exhibit 99.1 and aims to provide insights into the company’s operations, financial health, and future prospects. The release of such materials is significant for investors and analysts as it may affect the company's stock performance and market perception. The filing reflects Cytokinetics' ongoing commitment to transparency and communication with its shareholders.
  • : SEC 8-K (8.01): Cytokinetics, Incorporated announced the European Commission's approval of MYQORZO® (aficamten), a medication available in 5 mg, 10 mg, 15 mg, and 20 mg tablets, for treating symptomatic obstructive hypertrophic cardiomyopathy in adult patients classified as New York Heart Association (NYHA) class II-III. This approval represents a significant advancement in the treatment options for this condition, potentially impacting patient management and expanding market opportunities for Cytokinetics. The announcement confirms the regulatory approval dated February 17, 2026, showcasing strategic growth for the company's product portfolio.
  • : SEC 8-K (8.01): Cytokinetics, Incorporated announced on December 19, 2025, the FDA's approval of MYQORZO (aficamten) in multiple tablet doses (5 mg, 10 mg, 15 mg, and 20 mg) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This approval is significant as MYQORZO acts as an allosteric and reversible inhibitor of cardiac myosin motor activity, aimed at enhancing patients' functional capacity and alleviating symptoms associated with oHCM. The approval could have a substantial impact on patients by reducing cardiac contractility and left ventricular outflow tract obstruction, addressing a critical need in this patient population.
  • : SEC 8-K (8.01): Cytokinetics, Incorporated announced on December 12, 2025, that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended marketing authorization for MYQORZO® (aficamten), a drug intended for treating symptomatic obstructive hypertrophic cardiomyopathy in adult patients. This positive opinion could significantly impact Cytokinetics' market position, pending a final decision from the European Commission expected in the first quarter of 2026. The announcement includes forward-looking statements about the potential approval and associated risks, underscoring the uncertainty inherent in drug approvals.
  • : Cytokinetics Appoints Jeffrey J. Hessekiel as Executive Vice President, Chief Legal and Administrative Officer
  • : SEC 8-K (5.02): On November 13, 2025, Cytokinetics, Incorporated entered into an employment offer letter with Jeffrey J. Hessekiel, appointing him as the Executive Vice President, Chief Legal and Administrative Officer, effective November 14, 2025. Mr. Hessekiel previously served as Executive Vice President and General Counsel at Exelixis, Inc. from February 2014 to November 2025. His initial annual base salary will be $660,000, with a target bonus of 50% based on corporate and individual performance goals. This appointment is part of Cytokinetics' strategic move to strengthen its leadership team in the life sciences sector.
  • : SEC 8-K (5.02): On November 13, 2025, Cytokinetics, Incorporated entered into an employment offer letter with Jeffrey J. Hessekiel, who will serve as the Executive Vice President, Chief Legal and Administrative Officer starting November 14, 2025. Hessekiel, 56, previously worked as Executive Vice President and General Counsel at Exelixis, Inc. until November 2025. His previous roles include Senior Counsel at Arnold & Porter LLP. The appointment is strategic for Cytokinetics, focusing on enhancing its legal and administrative oversight as it advances its pipeline in the life sciences sector.

Cytokinetics funding history

DateRoundAmount
Jan 2022Funding RoundUndisclosed

Leadership

  • Jeffrey J. Hessekiel, Executive Vice President

Verified email and direct lines for Cytokinetics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

Cytokinetics files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Cytokinetics in the news

Companies similar to Cytokinetics

About Cytokinetics: questions and answers

What does Cytokinetics do?

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug c

Where is Cytokinetics headquartered?

Cytokinetics is headquartered in South San Francisco, California, United States.

How many employees does Cytokinetics have?

Cytokinetics has about 694 employees.

Has Cytokinetics raised funding?

Yes. Fundz has recorded 1 funding event for Cytokinetics. The most recent, Funding Round of Undisclosed, was in Jan 2022.

Who leads Cytokinetics?

Jeffrey J. Hessekiel is an Executive Vice President at Cytokinetics.

What is the latest news on Cytokinetics?

On Aug 28, 2026, SEC 8-K (8.01): On August 28, 2026, Cytokinetics, Incorporated announced through a press release the presentation of the full results of the ACACIA-HCM trial at the European Society of Cardiology (ESC) Congress 2026, with the results also published in the New England Journal of Medicine. This event

Is Cytokinetics a public company?

Yes. Cytokinetics is publicly traded under the ticker CYTK.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Cytokinetics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.